Prognostic significance of changes in heart rate following uptitration of beta-blockers in patients with sub-optimally treated heart failure with reduced ejection fraction in sinus rhythm versus atrial fibrillation.


Journal

Clinical research in cardiology : official journal of the German Cardiac Society
ISSN: 1861-0692
Titre abrégé: Clin Res Cardiol
Pays: Germany
ID NLM: 101264123

Informations de publication

Date de publication:
Jul 2019
Historique:
received: 02 08 2018
accepted: 18 12 2018
pubmed: 6 1 2019
medline: 18 12 2019
entrez: 6 1 2019
Statut: ppublish

Résumé

In patients with heart failure with reduced ejection fraction (HFrEF) on sub-optimal doses of beta-blockers, it is conceivable that changes in heart rate following treatment intensification might be important regardless of underlying heart rhythm. We aimed to compare the prognostic significance of both achieved heart rate and change in heart rate following beta-blocker uptitration in patients with HFrEF either in sinus rhythm (SR) or atrial fibrillation (AF). We performed a post hoc analysis of the BIOSTAT-CHF study. We evaluated 1548 patients with HFrEF (mean age 67 years, 35% AF). Median follow-up was 21 months. Patients were evaluated at baseline and at 9 months. The combined primary outcome was all-cause mortality and heart failure hospitalisation stratified by heart rhythm and heart rate at baseline. Despite similar changes in heart rate and beta-blocker dose, a decrease in heart rate at 9 months was associated with reduced incidence of the primary outcome in both SR and AF patients [HR per 10 bpm decrease-SR: 0.83 (0.75-0.91), p < 0.001; AF: 0.89 (0.81-0.98), p = 0.018], whereas the relationship was less strong for achieved heart rate in AF [HR per 10 bpm higher-SR: 1.26 (1.10-1.46), p = 0.001; AF: 1.08 (0.94-1.23), p = 0.18]. Achieved heart rate at 9 months was only prognostically significant in AF patients with high baseline heart rates (p for interaction 0.017 vs. low). Following beta-blocker uptitration, both achieved and change in heart rate were prognostically significant regardless of starting heart rate in SR, however, they were only significant in AF patients with high baseline heart rate.

Sections du résumé

BACKGROUND BACKGROUND
In patients with heart failure with reduced ejection fraction (HFrEF) on sub-optimal doses of beta-blockers, it is conceivable that changes in heart rate following treatment intensification might be important regardless of underlying heart rhythm. We aimed to compare the prognostic significance of both achieved heart rate and change in heart rate following beta-blocker uptitration in patients with HFrEF either in sinus rhythm (SR) or atrial fibrillation (AF).
METHODS METHODS
We performed a post hoc analysis of the BIOSTAT-CHF study. We evaluated 1548 patients with HFrEF (mean age 67 years, 35% AF). Median follow-up was 21 months. Patients were evaluated at baseline and at 9 months. The combined primary outcome was all-cause mortality and heart failure hospitalisation stratified by heart rhythm and heart rate at baseline.
RESULTS RESULTS
Despite similar changes in heart rate and beta-blocker dose, a decrease in heart rate at 9 months was associated with reduced incidence of the primary outcome in both SR and AF patients [HR per 10 bpm decrease-SR: 0.83 (0.75-0.91), p < 0.001; AF: 0.89 (0.81-0.98), p = 0.018], whereas the relationship was less strong for achieved heart rate in AF [HR per 10 bpm higher-SR: 1.26 (1.10-1.46), p = 0.001; AF: 1.08 (0.94-1.23), p = 0.18]. Achieved heart rate at 9 months was only prognostically significant in AF patients with high baseline heart rates (p for interaction 0.017 vs. low).
CONCLUSIONS CONCLUSIONS
Following beta-blocker uptitration, both achieved and change in heart rate were prognostically significant regardless of starting heart rate in SR, however, they were only significant in AF patients with high baseline heart rate.

Identifiants

pubmed: 30610382
doi: 10.1007/s00392-018-1409-x
pii: 10.1007/s00392-018-1409-x
pmc: PMC6584244
doi:

Substances chimiques

Adrenergic beta-Antagonists 0

Types de publication

Journal Article Multicenter Study Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

797-805

Subventions

Organisme : Chief Scientist Office
ID : PCL/17/07
Pays : United Kingdom
Organisme : Chief Scientist Office
ID : PCL 17/07
Pays : United Kingdom
Organisme : FP7
ID : FP7-242209-BIOSTAT-CHF
Organisme : Dutch Heart Foundation
ID : CVON 2014-11 RECONNECT

Références

Circulation. 2004 Jul 20;110(3):247-52
pubmed: 15226218
Eur Heart J. 2005 Nov;26(21):2259-68
pubmed: 16040619
Ann Intern Med. 2009 Jun 2;150(11):784-94
pubmed: 19487713
J Am Coll Cardiol. 2009 Nov 3;54(19):1747-62
pubmed: 19874988
Am J Med. 2010 Mar;123(3):198-204
pubmed: 20193823
N Engl J Med. 2010 Apr 15;362(15):1363-73
pubmed: 20231232
Cardiovasc Ther. 2010 Apr;28(2):93-100
pubmed: 20398098
Lancet. 2010 Sep 11;376(9744):875-85
pubmed: 20801500
J Am Coll Cardiol. 2012 May 29;59(22):1938-45
pubmed: 22617188
Eur J Heart Fail. 2012 Jul;14(7):737-47
pubmed: 22622001
Eur J Heart Fail. 2012 Sep;14(9):1030-40
pubmed: 22733981
Eur Heart J. 2013 May;34(20):1468-70
pubmed: 23324547
JACC Heart Fail. 2013 Feb;1(1):21-8
pubmed: 24621795
JACC Heart Fail. 2013 Feb;1(1):29-30
pubmed: 24621796
JACC Heart Fail. 2013 Dec;1(6):500-7
pubmed: 24622002
JACC Heart Fail. 2014 Jun;2(3):213-20
pubmed: 24952686
Lancet. 2014 Dec 20;384(9961):2235-43
pubmed: 25193873
Eur Heart J. 2015 Mar 14;36(11):669-75
pubmed: 25368202
Am J Med. 2015 Oct;128(10):1102-1108.e6
pubmed: 26044936
Circ Heart Fail. 2015 Sep;8(5):871-9
pubmed: 26243796
Eur J Heart Fail. 2015 Nov;17(11):1182-91
pubmed: 26358762
Clin Ther. 2015 Oct 1;37(10):2215-24
pubmed: 26391145
JACC Heart Fail. 2016 Feb;4(2):109-115
pubmed: 26519996
Eur J Heart Fail. 2016 Jun;18(6):716-26
pubmed: 27126231
Eur Heart J. 2016 Jul 14;37(27):2129-2200
pubmed: 27206819
Eur J Heart Fail. 2016 Aug;18(8):891-975
pubmed: 27207191
JACC Heart Fail. 2017 Feb;5(2):99-106
pubmed: 28089316
Eur Heart J. 2017 Jun 21;38(24):1883-1890
pubmed: 28329163
Clin Res Cardiol. 2017 Sep;106(9):711-721
pubmed: 28434020
Clin Res Cardiol. 2017 Dec;106(12):960-973
pubmed: 28795299
N Engl J Med. 2018 Feb 01;378(5):417-427
pubmed: 29385358
Clin Res Cardiol. 2018 Nov;107(11):1040-1049
pubmed: 29774407

Auteurs

Ify R Mordi (IR)

Division of Molecular and Clinical Medicine, Medical Research Institute, Mailbox 2, Ninewells Hospital & Medical School, University of Dundee, Dundee, DD1 9SY, UK. i.mordi@dundee.ac.uk.

Bernadet T Santema (BT)

Department of Cardiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.

Mariëlle Kloosterman (M)

Department of Cardiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.

Anna-Maria Choy (AM)

Division of Molecular and Clinical Medicine, Medical Research Institute, Mailbox 2, Ninewells Hospital & Medical School, University of Dundee, Dundee, DD1 9SY, UK.

Michiel Rienstra (M)

Department of Cardiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.

Isabelle van Gelder (I)

Department of Cardiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.

Stefan D Anker (SD)

Division of Cardiology (CVK), and Berlin-Brandenburg Center for Regenerative Therapies (BCRT), German Centre for Cardiovascular Research (DZHK) partner site Berlin, Charité Universitätsmedizin Berlin, Berlin, Germany.
Department of Cardiology, Universitätsmedizin Göttingen (UMG), Göttingen, Germany.

John G Cleland (JG)

National Heart and Lung Institute, Royal Brompton & Harefield Hospitals, Imperial College, London, UK.

Kenneth Dickstein (K)

University of Bergen, Bergen, Norway.
Stavanger University Hospital, Stavanger, Norway.

Gerasimos Filippatos (G)

National and Kapodistrian University of Athens, School of Medicine, Athens, Greece.
Department of Cardiology, Heart Failure Unit, Athens University Hospital Attikon, Athens, Greece.

Pim van der Harst (P)

Department of Cardiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.

Hans L Hillege (HL)

Department of Cardiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.

Marco Metra (M)

Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, Institute of Cardiology, University of Brescia, Brescia, Italy.

Leong L Ng (LL)

Department of Cardiovascular Sciences, University of Leicester, Glenfield Hospital, Leicester, UK.

Wouter Ouwerkerk (W)

Department of Clinical Epidemiology, Biostatistics, and Bioinformatics, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands.
National Heart Centre Singapore, 5 Hospital Drive, Singapore, Singapore.

Piotr Ponikowski (P)

Department of Heart Diseases, Wroclaw Medical University, Wrocław, Poland.
Cardiology Department, Military Hospital, Wrocław, Poland.

Nilesh J Samani (NJ)

Department of Cardiovascular Sciences, University of Leicester, Glenfield Hospital, Leicester, UK.
NIHR Leicester Biomedical Research Centre, Glenfield Hospital, Leicester, LE3 9QP, UK.

Dirk J van Veldhuisen (DJ)

Department of Cardiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.

Aeilko H Zwinderman (AH)

Department of Epidemiology, Biostatistics and Bioinformatics, Academic Medical Center, Inserm CIC 1433, Amsterdam, The Netherlands.

Faiez Zannad (F)

Inserm CIC-P 1433, Université de Lorraine, CHRU de Nancy, FCRIN INI-CRCT, Nancy, France.

Adriaan A Voors (AA)

Department of Cardiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.

Chim C Lang (CC)

Division of Molecular and Clinical Medicine, Medical Research Institute, Mailbox 2, Ninewells Hospital & Medical School, University of Dundee, Dundee, DD1 9SY, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH